Liposomal quercetin: Evaluating drug delivery in vitro and biodistribution in vivo

Expert Opinion on Drug Delivery

Volumn 9, Issue 6, 2012, Pages 599-613

  Gang, Wang ^a   Jie, Wang Jun ^a   Ping, Zhang Li ^a   Ming, Du Shi ^a   Ying, Liu Ju ^a   Lei, Wang ^a   Fang, Ye ^a  

^a HUBEI UNIVERSITY OF MEDICINE   (China)

Author keywords

Biodistribution; Cancer; Drug delivery; Nanomaterials; PEG2000 DPSE; Quercetin; Targeting

Indexed keywords

1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N [METHOXY(POLYETHYLENE GLYCOL) 2000]; ANTINEOPLASTIC AGENT; DRUG CARRIER; DRUG VEHICLE; LIPOSOME; MACROGOL 2000; NANOPARTICLE; QUERCETIN; TRYPAN BLUE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; CANCER INHIBITION; CELL KILLING; CELL VIABILITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; GLIOMA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHYSICAL CHEMISTRY; RAT; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL; ULTRAVIOLET SPECTROSCOPY;

ANIMAL STRUCTURES; ANIMALS; ANTIOXIDANTS; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DELIVERY SYSTEMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIOMA; LIPOSOMES; NANOSTRUCTURES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; QUERCETIN; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 84862091669     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.679926     Document Type: Article

References (66)

1. O'Driscoll CM, Griffin BT. Biopharmaceutical challenges associated with drugs with low aqueous solubility - the potential impact of lipid-based formulations. Adv Drug Deliv Rev 2008;60:617-24
2. Xavier CP, Lima CF, Rohde M, et al. Quercetin enhances 5-fluorouracil -induced apoptosis in MSI colorectal cancer cells through p53 modulation. Cancer Chemother Pharmacol 2011;68:1449-57
3. Siegelin MD, Reuss DE. Quercetin promotes degradation of surviving and thereby enhances death-receptor-mediated apoptosis in glioma cells. Neuro-oncol 2009;6:123-9
4. Heijnen CG, Haenen GR, van Acker FA, et al. Flavonoids as peroxynitrite scavengers: the role of the hydroxyl groups. Toxicology in Vitro 2001;15(1):3-6 (Pubitemid 32226368)
5. Robaszkiewicz A, Balcerczyk A, Bartosz G. Antioxidative and prooxidative effects of quercetin on A549 cells. Cell Biology International 2007;31:1245-50 (Pubitemid 47030992)
6. Lugli E, Ferraresi R, Roat E, et al. Quercetin inhibits lymphocyte activation and proliferation without inducing apoptosis in peripheral mononuclear cells. Leukemia Research 2009;33:140-50
7. Sun M, Gao Y, Pei Y, et al. Development of nanosuspension formulation for oral delivery of quercetin. J Biomed Nanotechnol 2010;6:325-32
8. Li H, Zhao X, Ma Y, et al. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 2009;133:238-44
9. Sahoo NG, Kakran M, Shaal LA, et al. Preparation and characterization of quercetin nanocrystals. J Pharm Sci 2011;100:2379-90
10. Wu TH, Yen FL, Lin LT, et al. Preparation, physicochemical characterization, and antioxidant effects of quercetin nanoparticles. Int J Pharm 2008;346:160-8
11. Smith AJ, Kavuru P, Wojtas L, et al. Cocrystals of quercetin with improved solubility and oral bioavailability. Mol Pharm 2011;8:1867-76
12. Kim MK, Park KS, Lee C, et al. Enhanced stability and intracellular accumulation of quercetin by protection of the chemically or metabolically susceptible hydroxyl groups with apivaloxymethyl (POM) promoiety. J Med Chem 2010;53:8597-607
13. Chetoni P, Rossi S, Burgalassi S, et al. Comparison of liposome encapsulated acyclovir with acyclovir ointment: ocular pharmacokineticsin rabbits. J Ocul Pharmacol Ther 2004;20:169-77 (Pubitemid 38456590)
14. Jesorka A, Orwar O. Liposomes: technologies and analytical applications. Annu Rev Anal Chem 2008;1:801-32
15. Harrington KJ, Lewanski CR, Northcote AD, et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol 2001;12:493-6 (Pubitemid 32472103)
16. Crielaard BJ, van der Wal S, Le HT, et al. Liposomes as carriers for colchicine-derived prodrugs: Vascular disrupting nanomedicines with tailorable drug release kinetics. Eur J Pharm Sci. 2012;45(4):429-35
17. Wu FG, Luo JJ, Yu ZW. Infrared spectroscopy reveals the nonsynchronicity phenomenon in the glassy to fluid micellar transition of DSPE-PEG2000 aqueous dispersions. Langmuir 2010;26:12777-84
18. Sochanik A, Mitrus I, Smolarczyk R, et al. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent. Arch Immunol Ther Exp (Warsz) 2010;58:235-45
19. Moribe K, Maruyama S, Inoue Y, et al. Ascorbyl dipalmitate/PEG-lipid nanoparticles as a novel carrier for hydrophobic drugs. Int J Pharm 2010;387:236-43
20. Gaber NN, Darwis Y, Peh KK, et al. Characterization of polymeric micelles for pulmonary delivery of beclomethasone dipropionate. J Nanosci Nanotechnol 2006;6:1-7
21. Torchilin VP. Polymer-coated long-circulating microparticulate pharmaceuticals. J Microencapsul 1998;15:11-19
22. Zalipsky S. Long circulating, cationic liposomes containing amino-PEG-phosphatidylethanolamine. FEBS Lett 1994;353:71-4 (Pubitemid 24312546)
23. Allen C, Maysinger D, Eisenberg A. Nano-engineering block copolymer aggregates for drug delivery. Colloids Surf B Biointerfaces 1999;16:23-7
24. Jones MC, Leroux JC. Polymeric micelles - a new generation of colloidal drug carriers. Eur J Pharm Biopharm 1999;48:101-11
25. Lukyanov AN, Gao Z, Torchilin VP. Micelles from polyethylene glycol/ phosphatidylethanolamine conjugates for tumor drug delivery. J Control Release 2003;91:97-102 (Pubitemid 37288880)
26. Veronese F, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10:1451-8 (Pubitemid 41483874)
27. Jiang W, Mardyani S, Fischer H, et al. Design and characterization of lysine cross-linked mercapto-acid biocompatible quantum dots. Chem Mater 2006;4:872-8
28. Mulder WJM, Koole R, Brandwijk RJ, et al. Surfactant-assisted synthesis of water-soluble and biocompatible semiconductor quantum dot ratlles. Nano Lett 2006;6:1-6
29. Adams M, Lavasanifar A, Kwon G. Amphiphilic block copolymers for drug delivery. J Pharm Sci 2003;92:1343-55 (Pubitemid 36792748)
30. Kwon GS, Suwa S, Yokoyama M, et al. Enhanced tumor accumulation and prolonged circulation times of ratlle-forming poly(ethylene oxideaspartate) block copolymer-adriamycin conjugates. J Control Release 1994;29:17-23 (Pubitemid 24104093)
31. Li Y, Kwon GS. Methotrexate esters of poly(ethylene oxide)-block-poly (2-hydroxyethyl-laspartamide). I. Effects of the level of methotrexate conjugation on the stability of ratlles and on drugrelease. Pharm Res 2000;17:607-11 (Pubitemid 30416400)
32. Nishiyama N, Kataoka K. Preparation and characterization of size-controlled polymeric ratlle containing cis-dichlorodiammineplatinum (II) in the core. J Control Release 2001;74:83-94 (Pubitemid 32727612)
33. Burt HM, Zhang X, Toleikis P, et al. Development of copolymers of poly(d, llactide) and methoxypolyethylene glycol as ratllar carriers of paclitaxel. Colloids Surf B Biointerfaces 1999;16:161-71 (Pubitemid 29486803)
34. Kohler N, Fryxell GE, Zhang MQ. A bifunctional poly(Ethylene Glycol) silane immobilized on metallic oxide-based nanoparticles for conjugation with cell targeting agents. J Am Chem Soc 2004;126:7206-11 (Pubitemid 38747770)
35. Larsen EK, Nielsen T, Wittenborn T, et al. Size-dependent accumulation of pegylated silane-coated magnetic iron oxide nanoparticles in murine tumors. ACS Nano 2009;3:1947-51
36. Wang A, Gu F, Zhang L, et al. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther 2008;8:1063-70
37. Ryan SM, Mantovani G, Wang X, et al. Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin Drug Deliv 2008;5:371-83 (Pubitemid 351721718)
38. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7:573-84 (Pubitemid 47106628)
39. Wang G, Wang JJ, Du SM, et al. Effects of quercetin nanoliposomes on C6 glioma cells through induction of type III programmed cell death. Int J Nanomedicine 2012;7:271-80
40. Siegelin MD, Reuss DE, Habel A, et al. Quercetin promotes degradation of survivin and thereby enhances death-receptor - mediated apoptosis in glioma cells. Neuro-oncol 2009;3:122-31
41. Xin H, Sha X, Jiang X, et al. The brain targeting mechanism of angiopep-conjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) nanoparticles. Biomaterials 2012;33:1673-81
42. Tian XH, Lin XN, Wei F, et al. Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int J Nanomed 2011;6:445-52
43. Ishida T, Harada M, Wang XY, et al. Accelerated blood clearance of PEGylated liposomes following preceding liposome administration: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J Control Release 2005;105(3):305-17 (Pubitemid 40941995)
44. Koide H, Asai T, Hatanaka K, et al. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated administration of PEGylated liposomes. Int J Pharm 2010;392(1-2):218-23
45. Ishida T, Atobe K, Wang X, et al. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicinencapsulation and high-dose first injection. J Control Release 2006;115(3):251-8 (Pubitemid 44634849)
46. Ishihara T, Takeda M, Sakamoto H, et al. Accelerated blood clearance phenomenon upon repeated injection of PEG modified PLA-nanoparticles. Pharm Res 2009;26(10):2270-9
47. Hofheinz RD, Gnad-Vogt SU, Beyer U, et al. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 2005;16:691-707 (Pubitemid 41104918)
48. Ghosh A, Mandal AK, Sarkar S, et al. Nanoencapsulation of quercetin enhances its dietary efficacy in combating arsenic-induced oxidative damage in liver and brain of rats. Life Sci 2009;84:75-80
49. Vicentini FT, Simi TR, Del Ciampo JO, et al. Quercetin in w/o microemulsion: in vitro and in vivo skin penetration and efficacy against UVB-induced skin damages evaluated in vivo. Eur JPharm Biopharm 2008;69:948-57
50. Kale R, Saraf M, Juvekar A, et al. Decreased B16F10 melanoma growth and impaired tumour vascularization in BDF1 mice with quercetin-cyclodextrin binary system. J Pharm Pharmacol 2006;58:1351-8 (Pubitemid 44580565)
51. Zarif L. Drug delivery by lipid cochleates. Methods Enzymol 2005;391:314-29 (Pubitemid 40254043)
52. Ahmed F, Discher DE. Self-porating polymersomes of PEG - PLA and PEG - PCL: hydrolysis triggered controlled release vesicles. J Control Release 2004;96(1):37-53 (Pubitemid 38438488)
53. Cai S, Vijayan K, Cheng D, et al. Micelles of different morphologies - advantages of worm-like filomicelles of PEO - PCL in paclitaxel delivery. Pharm Res 2007;24(6):2099-109 (Pubitemid 47493571)
54. Ahmed F, Pakunlu RI, Srinivas G, et al. Shrinkage of a rapidly growing tumor by drug-loaded polymersomes: pH-triggered release through copolymer degradation. Mol Pharm 2006;3(3):340-50 (Pubitemid 44021440)
55. Tokiwa Y, Jarerat A. Biodegradation of poly(L-lactide). Biotechnol Lett 2004;26(10):771-7 (Pubitemid 38982853)
56. Kumar N, Ravikumar MN, Domb AJ. Biodegradable block copolymers. Adv Drug Deliv Rev 2001;53(1):23-44 (Pubitemid 33152832)
57. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997;28(1):5-24 (Pubitemid 27497671)
58. Siepmann J, Gopferich A. Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv Drug Deliv Rev 2001;48(2-3):229-47 (Pubitemid 32434405)
59. Klibanov AL, Maruyama K, Torchilin VP, et al. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990;268(1):235-7 (Pubitemid 20233874)
60. Lee JC, Wong DT, Discher DE. Direct measures of large, anisotropic strains in deformation of the erythrocyte cytoskeleton. Biophys J1999;77(2):853-64 (Pubitemid 29362457)
61. Photos PJ, Bacakova L, Discher B, et al. Polymer vesicles in vivo: correlations with PEG molecular weight. J Control Release 2003;90(3):323-34 (Pubitemid 36859964)
62. Bermudez H, Brannan AK, Hammer DA, et al. Molecular weight dependence of polymersome membrane structure, elasticity, and stability. Macromolecules 2002;35(21):8203-8 (Pubitemid 35173635)
63. Dalhaimer P, Bates FS, Discher DE. Single molecule visualization of stable, stiffness-tunable, flow-conforming worm micelles. Macromolecules 2003;36(18):6873-7
64. Geng Y, Dalhaimer P, Cai S, et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nano 2007;2(4):249-55 (Pubitemid 46739812)
65. Dams ET, Laverman P, Oyen WJ, et al. Accelerated blood clearance and altered biodistribution of repeated administration of sterically stabilized liposomes. J Pharmacol Exp Ther 2000;292(3):1071-9 (Pubitemid 30136603)
66. Ishida T, Ichikawa T, Ichihara M, et al. Effect of the physicochemical properties of initially administrate liposomes on the clearance of subsequently administrate PEGylated liposomes in mice. J Control Release 2004;95(3):403-12 (Pubitemid 38340491)